Despite a pointed decision by the Federal Circuit vacating and remanding the matter to the Patent Trial and Appeal Board, yesterday the Board once again granted priority for CRISPR technology to the Broad Institute. A more detailed discussion of the basis for this judgment will follow.
Patent Law Weblog
recent posts
- Ex parte Chowdhury (PTAB 2026)
- Biofer S.P.A. v. Vifor (International) AG (Fed Cir. 2026)
- Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026)
- Patentees File Claim under 28 U.S.C. § 1498 before Court of Federal Claims, and Federal Government Files Motion to Dismiss under 28 U.S.C. § 1500
- Amici Address Section 1498 Scope in Moderna COVID-19 Infringement Appeal: In Favor of Reversal
Leave a comment